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Progressive renal fibrosis is the final common pathway
leading to renal failure irrespective of the initiating cause.
Clinical studies of renal fibrosis found that prominent mast
cell accumulation correlated with worse outcomes. Mast cells
are pluripotent innate immune cells that synthesize and
secrete profibrotic mediators. Here we use mast cell–deficient
(KitW-sh/W-sh) mice to define a functional pathogenic role for
these cells in the development of renal fibrosis. Intrarenal
collagen deposition was significantly decreased in mast
cell–deficient compared to wild-type mice 7 and 14 days after
unilateral ureteric obstruction. The intrarenal expression of
mRNAs for transforming growth factor-b, a-smooth muscle
actin, chemokines, and renal macrophages and CD4þ
T cells were also decreased in mast cell–deficient mice.
Reconstitution of the mast cell population in mast
cell–deficient mice with wild-type bone marrow–derived mast
cells restored the pattern and intensity of renal fibrosis to
levels seen in wild-type mice following ureteric ligation.
Interestingly, the mast cells were recruited, activated, and
degranulated within 6h of ureteric ligation. A mast cell
stabilizer that impairs degranulation, disodium
chromoglycate, significantly attenuated renal fibrosis
following ureteric ligation in wild-type mice. Thus, mast cells
promote renal fibrosis and their targeting may offer
therapeutic potential in the treatment of renal fibrosis.
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Fibrosis is a common final mechanism of organ injury,
including chronic kidney disease, where progressive fibrosis is
associated with worsening renal function.1,2 The histological
description of renal fibrosis includes: increased interstitial
matrix deposition with fibroblast accumulation, the recruit-
ment of inflammatory cells, the loss of tubular architecture,
and changes to the surrounding microvasculature.3 Unilateral
ureteric obstruction (UUO) is an experimental model
commonly used to study renal interstitial fibrosis and
inflammation. Many of the factors driving fibrosis and injury
in UUO have also been correlated with human fibrotic
kidney disease. These include increased expression of
transforming growth factor-b (TGFb),4 increased expression
of the myofibroblast marker a-smooth muscle actin (aSMA),5
and the presence of tissue proteases including matrix
metalloproteinases (MMPs).6 Progressive renal injury in
UUO is also accompanied by enhanced interstitial leukocyte
recruitment with increased numbers of CD4þ T cells,7
macrophages,8 and mast cells.9
Mast cells have traditionally been linked to immunoglo-
bulin E–mediated hypersensitivity, asthma, and host defense
against parasites. While mast cells are well known for their
immunoglobulin E Fce receptors, they are endowed with
multiple receptors allowing for the detection and response to
numerous pathological insults. These include threats posed
by pathogen- and danger-associated molecular patterns.
Mast cells are present at strategic locations including skin
surfaces and solid organs, where they are located near vessels
and nerve endings. This tactical positioning allows them to
act as ‘sentinels’ and first responders of host defense.10 As
well as a diffuse array of surface receptors, mast cells
synthesize and secrete chemokines, cytokines, growth
factors, and proteases, facilitating leukocyte recruitment
and microbial killing.11 Although they are sparse in solid
organs, their unusual capacity to store large quantities of
pre-formed molecules, which are released immediately upon
degranulation, allows them to mediate inflammation, injury,
and repair, despite their limited numbers. In addition to
their critical role in host survival from infection,12,13 the
diverse repertoire of functions has resulted in mast cells
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being linked with fibrosis, inflammation, and autoimmunity,
reviewed recently.9
Mice with mutations in c-kit expression or signaling are
deficient in mast cells; c-kit is essential for mast cell
differentiation. Historically many experimental studies exam-
ining mast cell function in vivo used Kitw/W-v mice. However,
while Kitw/W-v mice contain virtually no mast cells, they
display phenotypic abnormalities that are not related to mast
cell function. These abnormalities include: macrocytic anemia,
sterility, decreased lymphocyte counts, as well as increased
rates of dermatitis and gastric pathologies including cancers.14
More recently, mice where the effects of c-kit are more
restricted to mast cell deficiency alone, KitW-sh/W-sh mice, have
been described and published.14 KitW-sh/W-sh mice remain
equally mast cell deficient; however, they are fertile, have intact
immune systems, and are not anemic. These mice have been
extensively used to study the role of mast cells in vivo and
considering the phenotypic similarity to C57BL/6 wild-type
(WT) mice and are recommended for studying the physio-
logical function of mast cells in vivo.14 KitW-sh/W-sh mice have
been used to explore the role of mast cells in acute kidney
injury15 and chronic glomerulonephritis.16 Although addi-
tional factors could influence outcome results observed in
Kitw/W-v mice compared with mast cell-intact WT, changes
seen in KitW-sh/W-sh mice can be more accurately attributed to
mast cell deficiency. These observations can be confirmed
when KitW-sh/W-sh mice are reconstituted with mast cells from
WT mice and the patterns and severity of injury are
comparable to those seen in WT mice. Reconstitution of
KitW-sh/W-sh mice with bone marrow–derived mast cells from
WT mice results in normal numbers and function of mast
cells,14 including in the resting and diseased kidney.16
Mast cells are associated with a variety of renal diseases
and increased mast cell accumulation correlates with disease
severity and poorer outcome in chronic inflammation and
fibrosis (reviewed by Holdsworth and Summers9 and Mack
and Rosenkranz17). Experimentally mast cells demonstrate
both inflammatory16,18 and protective functions19–21 in the
kidney, which consistent with the diverse array of mediators
released. The role of mast cells in progressive kidney fibrosis
is less clearly defined. The correlation of mast cells with
injury and fibrosis suggests that they are mechanistically
linked to progressive fibrosis, although a pathogenic func-
tional role is not established. Mast cells contain an array of
potentially profibrotic mediators that include: chemokines,
growth factors (including TGFb), leukotrienes, and proteases
(including MMP3, MMP9, and MMP12),22,23 which could
enhance renal fibrosis. Potentially mast cell activation and
degranulation could result in the release of inflammatory and
profibrotic mediators promoting renal fibrosis and injury.
In this paper, we have defined a role for mast cells in renal
fibrosis induced by UUO. At 7 days after UUO, hydronephrotic
kidneys from WT mice had developed increased collagen
deposition, amplified expression of TGFb, aSMA, and MMP12,
and enhanced leukocyte recruitment. Mast cell–deficient,
KitW-sh/W-sh mice were protected from fibrotic injury induced
by UUO. Similarly, 14 days after ureteric ligation, protection
persisted in the absence of mast cells, with significantly
decreased intrarenal collagen and aSMA deposition in the
hydronephrotic kidneys of KitW-sh/W-sh mice. Furthermore,
when UUO was performed on KitW-sh/W-sh mice, which had
been reconstituted with bone marrow–derived mast cells from
WT mice, the pattern and severity of histological renal injury
seen in KitW-sh/W-sh mice was similar to that observed in WT
mice, demonstrating that mast cells were directly pathogenic
and profibrotic. Pre-emptive treatment with sodium chromo-
glycate, a mast cell stabilizer, protected WTmice from fibrosis
and renal injury. These results demonstrate that mast cells with
their pro-inflammatory mediators enhance renal fibrosis,
leukocyte recruitment, and injury after UUO.
RESULTS
Seven days after UUO, mast cell–deficient KitW-sh/W-sh mice
have decreased renal fibrosis
The development of fibrosis in the hydronephrotic kidney is
characterized by the deposition of collagen and aSMA in the
renal interstitium. We assessed renal collagen deposition after
picrosirius red staining, which was then analyzed using NIH
image analysis. Collagen deposition was increased in both WT
and KitW-sh/W-sh mice compared to untreated WT mice
(dotted line, mean¼ 2.4±0.4%). Compared to WT mice
collagen deposition was significantly decreased in KitW-sh/W-sh
mice 7 days after UUO (Figure 1a). Representative photo-
micrographs of the renal interstitium in WT and KitW-sh/W-sh
mice after picrosirius red staining are demonstrated in color
as viewed under polarized light (Figure 1b and c), in black
and white (Figure 1d and e), and after NIH image analysis
(Figure 1f and g). Interstitial aSMA deposition was also
decreased in KitW-sh/W-sh mice compared to WT mice after
NIH image analysis (Figure 2). In untreated WTmice, aSMA
deposition was consistently measured ato1%. Representative
images demonstrating decreased aSMA staining in color
(Figure 2b and c), black and white (Figure 2d and e), and after
analysis (Figure 2f and g) in KitW-sh/W-sh mice are shown.
Mast cells are recruited to hydronephrotic kidneys after UUO,
where they are activated and degranulated
Mast cells were easily detected in the lymph nodes of WT
mice (Figure 3a), while they were not seen in lymph nodes or
kidneys of KitW-sh/W-sh mice. Although infrequently observed,
mast cells were seen in the kidneys of WT mice, 7 days after
UUO (Figure 3b), after methyl Carnoy’s fixation and
toluidine blue staining. The serine protease chymase, which
is produced exclusively by mast cells and basophils, was
readily detected in the hydronephrotic kidneys of WT mice,
while levels of expression were at or below the lowest level of
detection in hydronephrotic kidneys from KitW-sh/W-sh mice
(Figure 3c); values were normalized to 1 in the hydrone-
phrotic kidneys of WT mice. The presence of mast cells and
the expression of chymase, a mast cell degranulation product,
provide evidence that mast cell activity was present in the
hydronephrotic kidneys of WT mice, even after 7 days.
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We hypothesized that mast cells were recruited to the
kidneys early in the disease process. To assess mast cell
activation (and degranulation), we performed UUO on WT
mice and assessed kidney tryptase production at time zero
and in the hydronephrotic kidneys at 6 h, 48 h, and 1 week
after ureteric ligation (Figure 3d). We found that mast cell
activation peaked 6 h after ureteric ligation, and tryptase
remained elevated after 48 h (5.2±1.2 ng/ml of tryptase) and
then decreased. At 1 week after UUO, kidney tryptase
production had fallen to similar levels recorded in untreated
WT mice.
To demonstrate conclusively mast cell recruitment to
hydronephrotic kidneys, we labeled mast cells with a cell
tracker and injected them into KitW-sh/W-sh mice, which lack any
endogenous mast cells. We then performed ureteric ligation and
assessed kidney mast cell accumulation, 6 h later. Mast cells
were readily detected in the hydronephrotic kidneys of injected
KitW-sh/W-sh mice after green staining (Figure 3e). Mast cells
were not present in the contralateral kidney (Figure 3f).
After ureteric ligation, kidney production and expression of
profibrotic growth factors were decreased in the absence of
mast cells
At 7 days after UUO, we measured TGFb production from
homogenized hydronephrotic kidneys of WT and KitW-sh/W-sh
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Figure 2 |The deposition of a-smooth muscle actin (aSMA) is
decreased in the absence of mast cells. (a) The deposition of
aSMA was significantly decreased in the hydronephrotic kidneys
of KitW-sh/W-sh mice (n¼ 8) compared to the hydronephrotic
kidneys of wild-type (WT) mice (n¼ 9). Representative kidney
sections demonstrating aSMA deposition in (b) WT and (c) KitW-sh/
W-sh mice visualized in color, viewed under polarized light, (d, e) in
black and white, and (f, g) after NIH image analysis are shown.
In untreated WT mice, aSMA deposition was measured at o1%.
All images are shown at original magnification  400. *Po0.05.
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Figure 1 |Renal fibrosis is decreased in mast cell–deficient
(KitW-sh/W-sh) mice. At 7 days after unilateral ureteric obstruction
(UUO), there was less interstitial collagen deposition (a) in the
kidneys of KitW-sh/W-sh mice (n¼ 8) compared to (C57BL/6) wild-
type (WT) mice (n¼ 9). Photomicrographs of collagen deposition
in WT and KitW-sh/W-sh mice after picrosirius red (PSR) staining are
shown. Representative kidney sections visualized in color, viewed
under polarized light, at original magnification  400 in (b) WT
and (c) KitW-sh/W-sh mice are shown, (d, e) in black and white, and
(f, g) after NIH image analysis. The dotted line represents the
mean collagen deposition in untreated WT mice. *Po0.05.
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mice. While TGFb production was increased in both groups
of experimental mice, compared to controls (where it was
undetectable), it was decreased in KitW-sh/W-sh mice, compared
to WTmice (Figure 4a). There was also a significant increase in
intrarenal mRNA expression of TGFb, aSMA, MMP3, and
MMP12 in the hydronephrotic kidneys of WTand KitW-sh/W-sh
mice compared to control kidneys (levels of expression in
untreated WT mice are represented by the dotted line). After
UUO, kidney expression of TGFb (Figure 4b), aSMA (Figure
4c), and MMP12 (Figure 4d) was decreased in KitW-sh/W-sh
mice compared to WT mice, while there was no change in
MMP2, MMP3, and MMP9 expression (Figure 4e–g). The
association of enhanced collagen and myofibroblast deposition
with increased kidney expression of profibrotic markers
highlighted a potential pathogenic role for mast cells in the
initiation and progression of renal fibrosis.
Seven days after UUO, kidney chemokine expression
and interstitial leukocyte recruitment were decreased in
KitW-sh/W-sh mice
We assessed the intrarenal expression of key leukocyte
chemoattractants. Intrarenal mRNA expression of chemokine
ligands (Figure 5a), which are chemoattractants for mono-
cytes CCL5 and T cells (CXCL9, CXCL10, and CCL20) were
all decreased in KitW-sh/W-sh mice. Assessing the neutrophil-
attracting chemokines, we found that CXCL2 expression was
reduced, while CXCL1 expression was unaltered between
experimental groups. Subsequently, we found that renal
interstitial macrophage and CD4þ T cell recruitment was
significantly decreased in KitW-sh/W-sh mice compared to WT
mice, while neutrophil recruitment was equivalent (Figure
5b–d and Supplementary Figure S1 online). These results
demonstrated that mast cells enhance the local production of
chemokines and leukocyte recruitment after ureteric ligation.
Fourteen days after UUO, fibrosis is significantly attenuated
in the absence of mast cells
To determine if the protection in fibrosis observed in the
absence of mast cells persisted after the first week, we
performed ureteric ligation in WT and KitW-sh/W-sh mice and
examined fibrosis in the hydronephrotic kidneys, 14 days
later. We found that intrarenal collagen deposition measured
after picrosirus red staining was decreased in the absence
of mast cells (Figure 6a). Similarly, aSMA deposition and
expression (Figure 6b and c) was decreased in the
hydronephrotic kidneys of KitW-sh/W-sh mice compared to
hydronephrotic kidneys from WT mice. There was no
difference in intrarenal TGFb expression between the two
groups (WT 1.0±0.3 vs. KitW-sh/W-sh mice 0.7±0.1-fold),
and values were normalized to 1 in the hydronephrotic
kidneys of WT mice.
Mast cell reconstitution restored the severity of fibrotic injury
in KitW-sh/W-sh mice
To confirm that the decreased fibrosis observed in KitW-sh/W-sh
mice was a direct consequence of mast cell deficiency, we
reconstituted KitW-sh/W-sh mice with bone marrow–derived
mast cells from WT mice. Successful reconstitution was
confirmed after demonstrating mast cells in the lymph nodes
and kidneys of mast cell–transplanted mice, as published
previously.15 After 12 weeks, when reconstitution was com-
plete, we performed UUO on mast cell–reconstituted KitW-sh/W-
sh mice and age-matched mast cell–deficient KitW-sh/W-sh mice.
We assessed renal fibrosis and injury 7 days later.
Reconstitution of KitW-sh/W-sh mice with mast cells from
WT mice followed by ureteric ligation resulted in a pattern
and severity of renal injury similar to that seen in
hydronephrotic kidneys of WT mice. Extracellular matrix
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Figure 3 |Mast cells were present in the kidneys of
hydronephrotic wild-type (WT) mice. (a) After toluidine blue
staining, mast cells were seen in the lymph nodes of untreated WT
mice at original magnification  400, demonstrated by the arrow
heads and in the white box (original magnification  1200).
(b) After fixation with methyl Carnoy’s solution and staining
with toluidine blue, mast cells were seen (occasionally) in the
hydronephrotic kidneys of WT mice, 7 days after unilateral ureteric
obstruction (UUO). At 7 days after UUO, chymase was detected in
the hydronephrotic kidneys of WT mice (n¼ 9), and the expression
was normalized to 1 in the hydronephrotic kidney of WT mice.
(c) Low levels of chymase expression were detected in the
hydronephrotic kidneys of KitW-sh/W-sh mice (n¼ 8). (d) Compared
to untreated WT mice (n¼ 6), mast cell activation and
degranulation peaked after 6 h (n¼ 4) and then decreased,
approaching baseline levels after 7 days (n¼ 4). Subsequently, we
labeled mast cells with a cell tracker and injected them into KitW-sh/
W-sh mice (n¼ 4). We then performed ureteric ligation and assessed
mast cell accumulation 6h later. (e) Mast cells (green) were readily
identified in the hydronephrotic kidneys, but were not seen in the
(f) contralateral, control kidney, original magnification  400.
**Po0.01, ***Po0.001.
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deposition was increased in reconstituted KitW-sh/W-sh mice
compared to control, un-reconstituted KitW-sh/W-sh mice
(Figure 7a). Representative black and white (Figure 7b and c)
and NIH image analyzed (Figure 7d and e) photomicro-
graphs demonstrate this result. Consistent with this finding,
we demonstrated a trend of increase in intrarenal TGFb
expression (P¼ 0.08), while aSMA expression was signifi-
cantly increased in reconstituted KitW-sh/W-sh mice (Figure 7f
and g). These studies provide direct evidence that mast cells
augment renal fibrosis after UUO.
Disodium chromoglycate, a mast cell stabilizer, decreased
renal fibrosis in UUO
Disodium chromoglycate is a commonly used therapeutic
agent, which impairs mast cell degranulation. To test the
therapeutic potential of DSCG in limiting renal fibrosis, we
administered DSCG or control, sterile saline, to WT mice 2
days before ureteric ligation and then on alternate days until
experiments ended (day 7). Administration of DSCG to WT
mice resulted in decreased extracellular matrix deposition
(Figure 8a–e) compared to WT mice treated with control.
Furthermore, there was a decrease in intrarenal TGFb
and aSMA expression in mice treated with DSCG
(Figure 8f and g). These results confirmed the role of mast
cell degranulation in promoting renal fibrosis and high-
lighted the therapeutic potential of DSCG in the treatment of
renal fibrosis.
DISCUSSION
Mast cells have been implicated in several different types of
kidney disease. Numerically mast cell accumulation correlates
positively with increased renal injury and decreased function
in immunoglobulin A nephropathy, diabetic nephropathy,
allograft rejection, amyloidosis, renovascular disease,
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Figure 4 | The expression and production of profibrotic markers were decreased in hydronephrotic kidneys from KitW-sh/W-sh mice.
(a) At 7 days after unilateral ureteric obstruction (UUO), production of transforming growth factor-b (TGFb) was highly significantly
decreased in the hydronephrotic kidneys of KitW-sh/W-sh mice (n¼ 8) compared to hydronephrotic wild-type (WT) kidneys (n¼ 9). (b–d)
Similarly, mRNA expression levels of TGFb, a-smooth muscle actin (aSMA), and matrix metalloproteinase 12 (MMP12) were all decreased in
the hydronephrotic kidneys of KitW-sh/W-sh mice compared to WT mice. (e–g) There was no difference in the MMP2, MMP3, or MMP9 kidney
expression between the two experimental groups. The dotted line represents the mean value recorded in untreated WT mice. *Po0.05,
***Po0.001.
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polycystic kidney disease, and drug-induced nephritis.9
Experimental studies have largely been confirmatory, linking
mast cell numbers and staining intensity with increased
TGFb production and interstitial fibrosis.9,17,24,25 These
studies suggest that mast cells are associated with the
development of renal fibrosis; however, a causal relationship
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is not established. In this paper, we demonstrate a direct
pathogenic role for mast cells in the promotion of renal
interstitial fibrosis induced by UUO. Evidence for a direct
pathogenic role for mast cells is strong and comes from three
lines of experimental data. Firstly, mast cell–deficient mice
develop less renal fibrosis compared to mast cell–replete mice.
This attenuation in fibrosis observed in KitW-sh/W-sh extended
to 14 days after UUO. A direct role for mast cells was
confirmed when the mast cell population was reconstituted
in mast cell–deficient mice and injury levels were similar to
those observed in WT mice after UUO. Finally, we
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Figure 7 |Mast cells promote renal fibrosis. To assess the direct
pathogenicity of mast cells, we reconstituted KitW-sh/W-sh mice
with bone marrow–derived mast cells from wild-type (WT) mice.
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unilateral ureteric obstruction (UUO) on reconstituted
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black and white and after NIH image analysis. (f, g) Kidney
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images are shown at original magnification  400. *Po0.05,
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Figure 8 |Mast cell stabilization attenuated renal fibrosis.
To assess the clinical effect of mast cell stabilization, we pre-
emptively administered disodium chromoglycate (DSCG) (n¼ 10)
or control (sterile saline) (n¼ 10) to wild-type (WT) mice and then
performed unilateral ureteric obstruction (UUO). (a) Mice treated
with DSCG had decreased collagen deposition in their kidneys.
Representative kidney sections demonstrating collagen
deposition in (b, d) control and (c, e) DSCG-treated mice are
shown. Intrarenal mRNA expression of (f) TGFb and (g) a-smooth
muscle actin (aSMA) was decreased after treatment with DSCG. All
images are shown at original magnification  400. *Po0.05,
**Po0.01.
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demonstrated that inhibition of mast cell degranulation with
DSCG diminished renal fibrotic injury.
Mast cells contain a variety of bioactive mediators,
including growth factors, proteases, leukotrienes, cytokines,
and chemokines, many of these could potentially promote
fibrosis. Direct evidence that mast cells could increase
collagen deposition and fibrosis was first demonstrated
nearly two decades ago in a dermal hypersensitivity model.
In this model, mast cell activation stimulated TGFb
production from skin fibroblasts, which resulted in increased
collagen deposition.26 The pleiotropic cytokine, TGFb, has
diverse physiological roles in vivo including initiation and
control of fibrosis.27 The profibrotic effects of mast cells are
intricately linked with TGFb. Mast cells produce,26,28 and
activate TGFb, through the production of chymase.29
Interestingly, TGFb is also a potent mast cell chemoattrac-
tant.30,31 This self-perpetuating profibrotic cycle helps
explain the diminution in renal injury we observed in mast
cell–deficient mice after UUO. In KitW-sh/W-sh mice, decreased
fibrosis was accompanied by less intrarenal TGFb produc-
tion, while TGFb and chymase mRNA expression was also
significantly decreased. The full pattern of injury and
expression of fibrosis returned when the mast cell population
was successfully reconstituted. In addition to TGFb and
chymase production, mast cells contain other pre-formed
mediators that can induce fibrosis. In clinical studies, mast
cell degranulation products, including tryptase, positively
correlate with advancing renal injury in chronic kidney
disease.32 Mast cells also contain MMP3, MMP9, and
MMP12,22,23 which have been implicated in renal fibrosis.3
In experimental lung disease, MMP12 is upregulated and
promotes macrophage recruitment and fibrosis.33 In our
studies, MMP12 was decreased in KitW-sh/W-sh mice, con-
sistent with decreased renal fibrosis. Mast cell degranulation
results in the rapid release of these mediators that are likely to
promote fibrosis. Confirmatory and mechanistic proof for a
pathogenic role for mast cell degranulation was demonstrated
when we pre-emptively treated mice with DSCG. Adminis-
tering the mast cell stabilizer attenuated renal fibrosis and
decreased kidney TGFb and aSMA expression. Disodium
chromoglycate has been shown to have mast cell specificity,
and in a model of endotoxemic sepsis, administration of
DSCG exclusively decreased serum tumor necrosis factor
levels and survival in WT mice (this effect was not seen in
mast cell–deficient mice treated with DSCG).34
Few mast cells were seen in the hydronephrotic kidneys of
WT mice, 1 week after UUO. While intrarenal chymase
expression was detectable in the hydronephrotic kidneys 1
week after ureteric ligation, levels were similar to those seen
in untreated WT mice. Therefore, we assessed mast cell
accumulation and activation (tryptase production) early after
UUO. Consistent with their function as first responders to
inflammation and injury, we found that mast cells were
recruited and activated (degranulated) and released pro-
inflammatory mediators in the kidney within 6 h of ureteric
ligation. Kidney mast cell activity had significantly decreased
1 week after UUO and returned to levels seen in untreated
WT mice. Despite their early recruitment to the injured
kidney, the pathological profibrotic properties of mast cells
persist to (at least) 14 days, when fibrosis is attenuated in the
absence of mast cells.
In response to stress, mast cells degranulate and secrete
chemokines and cytokines that recruit leukocytes to areas of
inflammation that are required for host defense.12,13 In UUO,
leukocyte recruitment is increased and positively correlates
with renal fibrosis.35 Macrophages36 and CD4þ T cells7 have
been associated with progressive renal injury after UUO. We
found that intrarenal chemokine expression of CCL5 was
decreased with a trend of decrease in CCL2 expression in
KitW-sh/W-sh mice compared to WTmice after UUO. This was
associated with decreased interstitial macrophage recruitment.
Similarly, intrarenal expression of CXCL9 and CXCL10, two
key Th1-attracting chemokines and CCL20, a key Th17-
attracting chemokine, was decreased in KitW-sh/W-sh mice.
Decreased chemokine expression correlated with fewer CD4þ
T cells observed in the renal interstitium. These data add
credence to the hypotheses that after stress mast cell
degranulate and release chemokines. Increased chemokine
production results in the recruitment of pro-inflammatory
leukocytes that contribute to the development of renal fibrosis.
In both clinical and experimental studies, mast cells have
been shown to be profibrotic. Clinically this is well
demonstrated in lung fibroblasts,37 stenotic heart valves,38
and tumors,39 while experimentally this has been validated in
the skin,40 hepatic,41 and cardiac fibrosis42 models. While
mast cell accumulation correlates with deteriorating renal
function, a previous study examining the role of mast cells in
renal fibrosis did not find them to be pathogenic.43 These
authors observed increased fibrosis in Kitw/W-v mice after
UUO. Interestingly, they found enhanced leukocyte recruit-
ment (with intact chemokine expression) in the Kitw/W-v
mice. These results conflict with our findings of decreased
fibrosis, decreased chemokine expression, and decreased
interstitial leukocyte recruitment in KitW-sh/W-sh mice. Our
results are consistent with the physiological effects usually
attributed to mast cells. The most likely explanation for the
discrepancy in results rests with the multiple additional
phenotypic abnormalities seen in Kitw/W-v mice, which are
not a result of mast cell deficiency. Similar discrepancies in
results have been reported in experimental arthritis, where
protection afforded to Kitw/W-v mice was not transferred to
KitW-sh/W-sh mice, a likely consequence of the hematological
and immunological abnormalities consistently observed in
Kitw/W-v mice.44
In conclusion, we have provided definitive proof that mast
cell activation and degranulation promotes renal fibrosis.
Mast cells are recruited early to the obstructed kidney, where
they are activated; they release profibrotic factors and
chemokines, which subsequently recruit pro-inflammatory
leukocytes. This heightened inflammatory state results in
enhanced fibrosis, which persists for at least 2 weeks after
ureteric ligation. Inhibition of mast cell degranulation, with
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DSCG, diminished fibrosis and injury highlighting the
therapeutic potential of targeting mast cells in the treatment
of renal fibrosis.
MATERIALS AND METHODS
Experimental design and statistical analyses
The 8- to 10-week-old male WT (C57BL/6) and KitW-sh/W-sh mice
were used in all experiments. WTmice were purchased from Monash
University Animal Services (Melbourne, Victoria, Australia).
KitW-sh/W-sh mice were purchased from Jackson Laboratories
(Bar Harbor, ME) and bred at Monash University. Studies adhered
to the National Health and Medical Research Council of Australia
guidelines for animal experimentation. The left ureter was ligated
under general anesthesia and renal injury and fibrosis was studied
after: 6 h, 48 h, 7 days, or 14 days, as described previously.45
Disodium chromoglycate (Sigma-Aldrich, St Louis, MO) at a
dose of 10mg/kg was dissolved in sterile saline and injected at day
2 and then on alternate days for the duration of experiments.
Control mice were injected with equivalent volumes of sterile
saline. Data are expressed as mean±s.e.m. Data were analyzed
using Student’s t-test and GraphPad Prism (GraphPad Software,
San Diego, CA). A P-value of o0.05 was considered significant.
Assessment of renal fibrosis and interstitial macrophage,
CD4þ , and neutrophil staining
For assessment of fibrosis, kidney sections were fixed in Bouin’s
fixative and embedded in paraffin. Tissue sections (3 mm tissue)
from all mice were stained with picrosirius red (Sigma-Aldrich).
Collagen deposition was assessed under polarized light and
quantitated by NIH image analysis (Scion Image, Scion Corpora-
tion, Frederick, MD). A minimum of 10 low-power ( 100) fields
were assessed per animal, covering the whole kidney, while vascular,
periglomerular, and perivascular areas were excluded. Results are
expressed as the percentage of interstitial cortical area affected. For
assessment of aSMA deposition, we used aSMA 1A4mAb (DAKO,
Glostrup Denmark), followed by a rabbit anti-mouse biotinylated
secondary antibody (DAKO), streptavidin alkaline phosphatase
(DAKO), and visualized by a red alkaline phosphatase substrate
kit (Vector Laboratories, Burlingame, CA). For leukocyte staining,
kidney sections were fixed in periodate lysine paraformaldehyde for
4 h, and then washed with 20% sucrose solution and frozen in
liquid nitrogen. Tissue sections were cut and a three-layered
immunoperoxidase technique was used to stain for macrophages,
T cells, and neutrophils. The primary antibodies used were: FA/11
for macrophages GK1.5 (anti-mouse CD4; American Type Culture
Collection (ATCC), Manassas, VA) and RB6-8C5 (anti-Gr-1; DNAX,
Palo Alto, CA) for neutrophils. The secondary antibody used was
rabbit anti-rat biotin (BD Bioscience, North Ryde, Australia)
visualized with 3,30-diaminobenzidine (Sigma-Aldrich). A mini-
mum of 20 consecutive interstitial sections were assessed per animal
and results are expressed as cells per high-power field for neutrophils
and CD4þ T cells.46 For assessment of interstitial macrophage
recruitment, we used a previously published scoring system
reflecting the area covered by macrophages (1, 0–25%; 2, 26–50%;
3, 51–75%; and 4, 76–100%).47
Measurement of kidney TGFb production and intrarenal
mRNA expression of chemokines and cytokines
For measurement of kidney TGFb production, sections of hydro-
nephrotic kidneys from both groups of experimental mice were
digested in 1% cetyl trimethylammonium bromide and phosphate-
buffered saline for 2 h at room temperature. Samples were
centrifuged at 20,000 g. Supernatants were extracted and measured
using an enzyme-linked immunosorbent assay (R&D Systems,
Minneapolis, MN) according to the manufacturer’s protocol. For
measurement of RANTES/CCL5, MCP1/CCL2, MIG/CXCL9, IP10/
CXCL10, LARC/CCL20, KC/CXCL1, and MIP2/CXCL2, MMP2,
MMP3, MMP9, MMP12, TGFb, and aSMA, RNA was extracted
from the kidney and measured by real-time PCR, using
techniques and primers we have described previously.8,46 To
measure chymase expression, we used a Taqman Gene Expression
Array (Mm00487938_m1; Applied Biosystems, Melbourne, Victoria,
Australia). Expression was standardized to 18S (housekeeping gene)
before being expressed as a fold increase (or decrease) relative to
control.
Assessment of mast cell activation and degranulation
We performed unilateral ureteric ligation on WTmice and removed
the hydronephrotic kidneys after 6 h (n¼ 4), 48 h (n¼ 4), and after
1 week (n¼ 4), and for controls we used untreated WTmice (n¼ 6).
Kidneys were digested with collagenase and DNAse (both Roche
Diagnostics, Indianapolis, IN), incubated, and then centrifuged at
13,000 r.p.m. for 15min as described previously.15 An enzyme-
linked immunosorbent assay, from Millipore (IMM001, Billerica,
MA) was used to measure mast cell activation, according to the
manufacturer’s recommendations.
Mast cell reconstitution and staining in peripheral tissues
Bone marrow cells were harvested from 6- to 8-week-old WTmice.
Cells were filtered, spun, red blood cells were then lysed, and the
supernatant discarded. Cells were cultured in RPMI (Sigma-Aldrich)
using 15% fetal calf serum, 1% Pen/Strep, 2mmol/l L-glutamine,
1mmol/l sodium pyruvate, and 50 mm 2-M,E. Interleukin-3 (from
WEHI3 cell culture supernatants) and 12.5 ng/ml recombinant
mouse stem cell factor (R&D Systems) were added. Culture media
were changed every 3 days. After 8 weeks, mast cell purity (498%)
was assessed using a cyto-spinner after toluidine blue staining. A
total of 5 106 cells were injected intravenously into the mice.
We waited 12 weeks for full re-constitution to develop.14 Mast cells
were identified by staining lymph nodes and kidneys with toluidine
blue after fixation in methyl Carnoy’s solution. Reconstitution
was confirmed by staining for mast cells with toluidine blue in
peripheral tissues and kidneys as described previously.15 To
demonstrate that mast cells are recruited early to the obstructed
kidney, we labeled mature mast cells, after 8 weeks of culture
with a CellTracker (CMTPX) from Invitrogen (Newcastle,
New South Wales, Australia), this was dissolved in dimethylsulfoxide
to a concentration of 10mmol/l. Cells (30 106) were stained
with 20 mm CMPTX and incubated for 30min at 30 1C, spun
(12,000 r.p.m. for 7min), and resuspended in isotonic saline.
Labeled mast cells (1 106) were injected subcutaneously into the
base of tail of KitW-sh/W-sh mice. We then performed unilateral
ureteric ligation and removed the hydronephrotic and contralateral
kidneys, 6 h later. Kidney sections were viewed under immuno-
fluorescent light, Leica (Leica Microsystems, Wetzlar, Germany)
D300F using a filter 13, and images captured using Adobe
Photoshop.
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